From Pakistan to the Front Lines of Multiple Myeloma Research | OncLive Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.

From Pakistan to the Front Lines of Multiple Myeloma Research @szusmani.bsky.social @mskcancercenter.bsky.social #oncology #myeloma
www.onclive.com/view/from-pa...

Dr. Sumanta Pal of @cityofhope.bsky.social discusses the impact of the groundbreaking AQUILA trial in high-risk smoldering multiple myeloma with @vincentrk.bsky.social of Mayo Clinic & @szusmani.bsky.social of @mskcancercenter.bsky.social on the latest #ASCODailyNews Podcast: https://bit.ly/41FCEVw

#ASH25: Our collaborator María-Victoria Mateos will share results of a phase 3 study of teclistamab plus daratumumab for relapsed refractory #multiplemyeloma. #mmsm @mskcancercenter.bsky.social @ash.hematology.org @szusmani.bsky.social

TODAY | 8:45 a.m. EST

Learn more: bit.ly/3MN6MKr

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.

🗓️ Thursday, September 18 | 4:40 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm

🗓️ Friday, September 19 | 9:40 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm

🗓️ Saturday, September 20 | 9:20 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm

🗓️ Wednesday, September 17 | 11:10 a.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.

🗓️ Wednesday, September 17 | 12:14 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Sign up to read exclusive expert insights on key abstracts to watch at #IMS25! @szusmani.bsky.social @mskcancercenter.bsky.social @myeloma-society.bsky.social #mmsm
www.onclive.com/view/experts...

Join Dr. @szusmani.bsky.social as he presents research on "Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed #MM (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study" at #ASCO25. @ascocancer.bsky.social

"The phase 3 CEPHEUS trial previously demonstrated improved efficacy outcomes with DVRd vs VRd in patients with TIE or transplant-differed NDMM," shares myeloma specialist
@szusmani.bsky.social during his session at #ASCO25.

@ascocancer.bsky.social

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma @ascocancer.bsky.social @mskcancercenter.bsky.social @szusmani.bsky.social #ASCO25 #mmsm www.onclive.com/view/d-vrd-r...

Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and
@szusmani.bsky.social on being inducted into the 13th Giants of Cancer Care® class by @onclive.bsky.social! This award honors leading physicians who are advancing #cancerresearch. @mskcancercenter.bsky.social
Learn more: bit.ly/42Ox58M

❤️ Thank you, Dr. Usmani for continuing to support #MyelomaICE!

Dear all, putting in a plug for the International Myeloma Foundation Iceland Cycling Expedition 2025 below. Thanks for your generosity last year, many of you contributed to its success. Every donation and any amount counts.
@imfmyeloma.bsky.social
fundraise.myeloma.org/fundraiser/5...

1/ 🚨New research alert! 🚨Our study in Blood Cancer shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma, with @joedeasy.bsky.social, @malinhultcrantz.bsky.social, @szusmani.bsky.social, and the rest of the @mskcancercenter.bsky.social team! 🧵👇#MyelomaSky

NEW in @natmedicine.bsky.social: Results from a phase 3 clinical trial led by MSK's #myeloma specialist & cellular therapist @szusmani.bsky.social. Learn more: www.nature.com/articles/s41...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study - Nature Medicine In the phase 3 CEPHEUS trial, patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and d...

Quadruplets induction regimens are the established standards of care now in newly diagnosed MM, just out 🎉👇🏽
#MyelomaSky

@mskcancercenter.bsky.social
@imfmyeloma.bsky.social
@themmrf.bsky.social
@healthtreeorg.bsky.social

www.nature.com/articles/s41...

Thanks to @szusmani.bsky.social for donating 🙌🏾🙌🏾🙌🏾🥳🥳🥳 to support multiple myeloma cancer research @ give.themmrf.org/fundraiser/5...

This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social

6-8 p.m. PST
https://buff.ly/3ZLbSey
https://buff.ly/3OOjjeG
https://buff.ly/3Vum0Wv

Congratulations to MSK's Dr. Urvi Shah for being awarded the @ash-hematology.bsky.social David M. Goldenberg Clinical Research Training Institute Award for her work on research that shows that a high-fiber, plant-based dietary intervention may delay progression #MGUS/#SMM to #MM.

#ASH24 #ASHKudos

Dr. @szusmani.bsky.social presents on “Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept” that is part of the ASH Research Collaborative Multiple Myeloma Network at @ash-hematology.bsky.social.

#ASH24

Please join us now #ASH24
#MyelomaSky
ASH RESEARCH COLLABORATIVE MULTIPLE MYELOMA NETWORK: ACCELERATING RESEARCH AND COLLABORATIVE CLINICAL CARE THROUGH REAL-WORLD EVIDENCE GENERATION
December 7, 2024, 4:00 p.m. - 5:30 p.m.
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

#ASH24: Join myeloma specialist Dr. @szusmani.bsky.social for his presentation on "Working with Data Hub Data and Network PIs to Develop Evidence that Changes Practice in Multiple Myeloma: The COSMIC Study as Proof of Concept" today at 4pm PT at @ash-hematology.bsky.social.

bit.ly/49vscmW

Join Kylee Maclachlan for the presentation "Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease."

2:15 pm PST. #ASH24 @mskcancercenter.bsky.social
@szusmani.bsky.social @ash-hematology.bsky.social
buff.ly/4f6J3gP

☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern.

Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post!

🛑Remember, there's only one H in #ASHaiku!

#HemeSky #Hematology

592 Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
ash.confex.com/ash/2024/web...

766 Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
ash.confex.com/ash/2024/web...

672 Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
ash.confex.com/ash/2024/web...